Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
GLP-1 drugs and skin disease: the evidence
A 2026 dermatology review examines how GLP-1 receptor agonists, including tirzepatide, may affect psoriasis, hidradenitis suppurativa, acne, and wound healing.
GLP-1 Drugs and Pregnancy: A Trends Update
Real-world data show a gap between guideline recommendations and GLP-1 discontinuation timing around pregnancy. Here is what the evidence says.
Incretin drugs: outcomes before weight loss
A 2026 review ranks incretin therapies by CV mortality evidence first, weight loss second, and maps drug choice to patient phenotype via receptor pharmacology.
Lilly and the Medicare GLP-1 bridge program
The Medicare GLP-1 Bridge launched July 2026 at a $50 monthly copay. Lilly's Q2 numbers show the scale analysts are mapping against it.
GHK Cu and AHK Cu: topical evidence
What published GHK Cu research can and cannot establish about topical copper peptide claims, combinations, and personal exposure.
Thai holy basil and MASLD: a rat study
A 2026 rat study found Ocimum sanctum flower extract reduced lipid markers and liver inflammation in diet-induced MASLD. No human data exists.
A NAION case after semaglutide exposure
A 2026 case report describes NAION after recent semaglutide exposure. Here is what one case can show, and what it cannot.
Semaglutide withdrawal in type 1 diabetes
A small ADJUST T1D extension found lower time in range and greater glucose variability after semaglutide ended in adults using automated insulin delivery.
Surfactants and peptide stability
A 2026 formulation study found that surfactants can destabilise some therapeutic peptides under agitation stress. The effect depended on the peptide.
SURMOUNT-OSA: baseline factors
A post hoc SURMOUNT-OSA analysis found OSA-related improvements across baseline groups, but it does not predict an individual response.
Tirzepatide and unilateral Graves' disease
A 2026 case report describes unilateral Graves' disease developing in a patient with type 2 diabetes during tirzepatide treatment. No causal link established.
Weight Regain After Stopping GLP-1 Drugs
A 2026 Bayesian meta-analysis maps how quickly body weight returns after stopping semaglutide or tirzepatide and what the trajectory looks like over time.